IL141531A0 - Methods of using and compositions comprising dopamine reuptake inhibitors - Google Patents

Methods of using and compositions comprising dopamine reuptake inhibitors

Info

Publication number
IL141531A0
IL141531A0 IL14153199A IL14153199A IL141531A0 IL 141531 A0 IL141531 A0 IL 141531A0 IL 14153199 A IL14153199 A IL 14153199A IL 14153199 A IL14153199 A IL 14153199A IL 141531 A0 IL141531 A0 IL 141531A0
Authority
IL
Israel
Prior art keywords
disorders
dopamine reuptake
disorder
desmethylsibutramine
didesmethylsibutramine
Prior art date
Application number
IL14153199A
Other languages
English (en)
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of IL141531A0 publication Critical patent/IL141531A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Information Transfer Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL14153199A 1998-08-24 1999-08-23 Methods of using and compositions comprising dopamine reuptake inhibitors IL141531A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9766598P 1998-08-24 1998-08-24
US9930698P 1998-09-02 1998-09-02
US09/372,158 US6331571B1 (en) 1998-08-24 1999-08-11 Methods of treating and preventing attention deficit disorders
PCT/US1999/019167 WO2000010551A2 (en) 1998-08-24 1999-08-23 Methods of using and compositions comprising dopamine reuptake inhibitors

Publications (1)

Publication Number Publication Date
IL141531A0 true IL141531A0 (en) 2002-05-23

Family

ID=27378425

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14153199A IL141531A0 (en) 1998-08-24 1999-08-23 Methods of using and compositions comprising dopamine reuptake inhibitors
IL141531A IL141531A (en) 1998-08-24 2001-02-20 Use of a sibutramine metabolite for the manufacture of a medicament for treating attention deficit disorder (add)

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL141531A IL141531A (en) 1998-08-24 2001-02-20 Use of a sibutramine metabolite for the manufacture of a medicament for treating attention deficit disorder (add)

Country Status (21)

Country Link
US (3) US6331571B1 (xx)
EP (2) EP1475086A3 (xx)
JP (1) JP2002523366A (xx)
KR (3) KR100887008B1 (xx)
CN (1) CN100415222C (xx)
AT (1) ATE279184T1 (xx)
AU (2) AU772303B2 (xx)
CA (1) CA2341441C (xx)
CZ (1) CZ2001677A3 (xx)
DE (1) DE69921157T2 (xx)
DK (1) DK1107746T3 (xx)
ES (1) ES2226435T3 (xx)
HK (1) HK1088238A1 (xx)
HU (1) HUP0103408A3 (xx)
ID (1) ID28638A (xx)
IL (2) IL141531A0 (xx)
NO (1) NO20010943L (xx)
NZ (1) NZ510193A (xx)
PL (1) PL200264B1 (xx)
PT (1) PT1107746E (xx)
WO (1) WO2000010551A2 (xx)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6339106B1 (en) * 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6696495B2 (en) * 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
HUP0200495A3 (en) * 1999-03-19 2004-09-28 Abbott Gmbh & Co Kg Method of treating eating disorders
CN1660109A (zh) * 1999-07-01 2005-08-31 法玛西雅厄普约翰美国公司 高度选择性去甲肾上腺素再摄取抑制剂及其用途
US6399826B1 (en) * 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
AU2002210816A1 (en) * 2000-11-02 2002-05-15 Torrent Pharmaceuticals Ltd Process for preparation of beta-phenethylamine derivative
US20020115727A1 (en) * 2000-12-04 2002-08-22 Senanayake Chris H. Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines
DE60229123D1 (de) * 2001-02-20 2008-11-13 Dinan Timothy Gerard Behandlung von fibromyalgie mit pindolol
DE10142666A1 (de) * 2001-08-31 2003-03-20 Aventis Pharma Gmbh Verwendung von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US7005138B2 (en) * 2001-12-21 2006-02-28 Duramed Pharmaceuticals, Inc. Method of systematically delivering SSRIs
US20060263419A1 (en) * 2002-03-12 2006-11-23 Hans-Michael Wolff Transdermal therapeutic system for Parkinson's Disease
CN101444509A (zh) * 2002-05-30 2009-06-03 神经研究公司 治疗慢性疼痛的三单胺再摄取抑制剂
AU2003268361A1 (en) * 2002-08-30 2004-03-19 Watson Pharmaceuticals, Inc. Drug delivery system for treating urinary incontinence
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
US20050228052A1 (en) * 2004-01-29 2005-10-13 Barberich Timothy J Methods of treating, preventing and managing a sleep disorder using (S)-didesmethylsibutramine
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
ES2337700T3 (es) * 2004-02-18 2010-04-28 Sepracor, Inc. Terapia combinada de agonista de dopamina con sedantes para mejorar la calidad del sueño.
US20050266085A1 (en) * 2004-05-28 2005-12-01 Warner Kevin S Gelled emulsion and microemulsion formulations for dermal drug delivery
KR100618176B1 (ko) * 2004-12-02 2006-09-01 휴먼팜 주식회사 시부트라민 주석산염, 이의 제조 방법 및 이를 포함하는약학적 조성물
US20080207950A1 (en) * 2004-12-22 2008-08-28 Ciba Specialty Chemicals Corp. Enantioselective Synthesis of a Sterically Hindered Amine
KR20060080817A (ko) * 2005-01-06 2006-07-11 씨제이 주식회사 시부트라민의 디카복실산염
KR100830002B1 (ko) * 2005-01-06 2008-05-15 씨제이제일제당 (주) 시부트라민의 무기산염
KR20060080818A (ko) * 2005-01-06 2006-07-11 씨제이 주식회사 시부트라민의 술폰산염
KR20060093564A (ko) * 2005-02-22 2006-08-25 종근당바이오 주식회사 무수 시부트라민 말산염 및 이의 제조 방법
KR100632470B1 (ko) * 2005-02-25 2006-10-12 민연식 결정성 시부트라민 캄실레이트염과 이의 제조방법
JP2008536922A (ja) * 2005-04-22 2008-09-11 テバ・ファーマシューティカルズ・ユーエスエー・インコーポレイテッド オランザピンの医薬用経口崩壊錠
CA2612268A1 (en) * 2005-06-17 2006-12-28 Pfizer Products Inc. Metabolites of 1-[6-(1-ethyl-1-hydroxy-propyl)-pyridin-3-yl]-3-[2-(4-methyl-piperazin-1-yl)-benzyl]-pyrrolidin-2-one as seratonin receptor antagonists
JP2009529534A (ja) * 2006-03-10 2009-08-20 ザ・リサーチ・ファウンデーション・オブ・ステート・ユニバーシティ・オブ・ニューヨーク 中枢神経系活動に用いられるホモトロパン
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
NZ579170A (en) * 2007-02-12 2012-05-25 Dmi Biosciences Inc Reducing side effects of tramadol
EP2120570B1 (en) * 2007-02-12 2012-05-16 DMI Biosciences, Inc. Treatment of comorbid premature ejaculation and erectile dysfunction
WO2010022236A2 (en) * 2008-08-20 2010-02-25 The University Of Medicine And Dentistry Of New Jersey Inhibiting obesity progression by inhibiting adipocyte differentiation with a pre-adipocyte autophagy inhibitor
WO2010093243A1 (en) 2009-02-12 2010-08-19 Coöperatieve Mirzorg U.A., Arnhem Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
WO2010126970A1 (en) * 2009-04-28 2010-11-04 Optmed, Inc. Methods for treating and preventing erectile dysfunction
AU2011291506B2 (en) 2010-08-19 2016-07-28 Buck Institute For Age Research Methods of treating mild cognitive impairment (mci) and related disorders
NL2022615B1 (en) 2019-02-21 2020-08-31 Patrick Alexander Unger Pharmaceutical composition comprising tetrahydrocannabivarin for the prevention and treatment of overweight
CN113908295B (zh) * 2021-11-12 2023-07-21 郑州大学第一附属医院 一种阿普唑仑包合物及其制备方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155669A (en) 1962-06-22 1964-11-03 Res Lab Dr C Janssen N V 2, 4, 8-triaza-spiro (4, 5) dec-2-enes
US3155670A (en) 1962-06-22 1964-11-03 Res Lab Dr C Janssen N V 1-oxo-2, 4, 8, triaza-spiro (4, 5) decanes
US3471515A (en) 1965-02-01 1969-10-07 Sandoz Ag (2-hydroxy-3-substituted aminopropoxy)indoles
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
GB1308191A (en) 1970-04-06 1973-02-21 Science Union & Cie Thiochroman derivatives and a process for preparing them
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
DE3008993A1 (de) 1980-03-08 1981-10-01 Röhm Pharma GmbH, 6100 Darmstadt Pharmazeutische zubereitungen
ZA821577B (en) 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
IE52768B1 (en) 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
JPS5940638A (ja) 1982-08-30 1984-03-06 Fuji Photo Film Co Ltd 直接ポジ用ハロゲン化銀写真乳剤
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
GB8501192D0 (en) * 1985-01-17 1985-02-20 Boots Co Plc Therapeutic agents
GB8531071D0 (en) 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JP2675573B2 (ja) 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IE61928B1 (en) 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
GB8909209D0 (en) 1989-04-22 1989-06-07 Wyeth John & Brother Ltd Piperazine derivatives
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US5104899A (en) 1990-08-13 1992-04-14 Sepracor, Inc. Methods and compositions for treating depression using optically pure fluoxetine
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
EP0554172B1 (en) 1992-01-28 1998-04-29 Fujitsu Limited Color surface discharge type plasma display device
US5780051A (en) 1992-04-02 1998-07-14 Dynagen, Inc. Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
EP0708639A4 (en) 1992-06-23 1997-08-20 Sepracor Inc METHOD AND COMPOSITIONS FOR TREATMENT OF DEPRESSION AND OTHER DISEASES USING OPTICALLY PURE SIBUTTRAMINE
AU4542893A (en) 1992-06-23 1994-01-24 Sepracor, Inc. Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US5459164A (en) 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
GB9402641D0 (en) 1994-02-11 1994-04-06 Boots Co Plc Therapeutic agents
CA2134038C (en) 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
JP3823194B2 (ja) 1994-09-19 2006-09-20 アステラス製薬株式会社 ５ｈｔ▲３▼拮抗剤の新規医薬用途
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
GB9524681D0 (en) 1995-12-02 1996-01-31 Knoll Ag Chemical process
DE19632423A1 (de) 1996-08-12 1998-02-19 Merck Patent Gmbh Thienopyrimidine
GB9619757D0 (en) 1996-09-21 1996-11-06 Knoll Ag Chemical process
GB9619961D0 (en) 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9619962D0 (en) 1996-09-25 1996-11-13 Knoll Ag Medical treatment
US5795880A (en) 1996-12-30 1998-08-18 Louisiana State University Medical Center Foundation Method and composition for treating obesity and related disorders in animals comprising dehydroepiandrosterone (DHEA), or a derivative thereof, and an anorectic agent
US6127363A (en) 1997-10-28 2000-10-03 Vivus, Inc. Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunction
GB9727131D0 (en) 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
US6339106B1 (en) * 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction

Also Published As

Publication number Publication date
HUP0103408A2 (hu) 2002-05-29
DE69921157T2 (de) 2006-02-02
US6538034B2 (en) 2003-03-25
AU772303B2 (en) 2004-04-22
JP2002523366A (ja) 2002-07-30
KR20060081725A (ko) 2006-07-13
ATE279184T1 (de) 2004-10-15
US20020188029A1 (en) 2002-12-12
WO2000010551A3 (en) 2000-09-21
HK1088238A1 (en) 2006-11-03
PL200264B1 (pl) 2008-12-31
US7071234B2 (en) 2006-07-04
EP1475086A3 (en) 2006-12-13
US6331571B1 (en) 2001-12-18
ES2226435T3 (es) 2005-03-16
EP1107746A2 (en) 2001-06-20
PT1107746E (pt) 2005-03-31
WO2000010551A2 (en) 2000-03-02
CN100415222C (zh) 2008-09-03
IL141531A (en) 2010-05-31
CZ2001677A3 (cs) 2002-02-13
DK1107746T3 (da) 2005-02-14
CA2341441A1 (en) 2000-03-02
AU2004200875A1 (en) 2004-04-01
CA2341441C (en) 2011-07-19
CN1735407A (zh) 2006-02-15
HUP0103408A3 (en) 2002-10-28
AU5781799A (en) 2000-03-14
NO20010943L (no) 2001-04-23
ID28638A (id) 2001-06-21
DE69921157D1 (de) 2004-11-18
EP1107746B1 (en) 2004-10-13
NZ510193A (en) 2003-09-26
EP1475086A2 (en) 2004-11-10
US20030195261A1 (en) 2003-10-16
NO20010943D0 (no) 2001-02-23
KR20010085553A (ko) 2001-09-07
KR20080011354A (ko) 2008-02-01
KR100887008B1 (ko) 2009-03-04
PL346843A1 (en) 2002-02-25
AU2004200875B2 (en) 2006-10-26

Similar Documents

Publication Publication Date Title
HK1088238A1 (en) Methods of using and compositions comprising dopamine reuptake inhibitors
PL1678172T3 (pl) Związki azabicykliczne do łagodzenia bólu oraz leczenia zaburzeń centralnego układu nerwowego
JP2003524613A5 (xx)
CA2352324A1 (en) Derivatives of (-)-venlafaxine and methods of preparing and using the same
JP2003503450A5 (xx)
DK0812190T3 (da) R-enantiomer af N-propargyl-1-aminoindan til behandling af forskellige sygdomme og mesylat, esulat og sulfat deraf
NO975331L (no) Anvendelse av R-enantiomer av N-propargyl-1-aminoindan salter og sammensetninger derav
RU2009138602A (ru) Новые производные бензазепина
TW200635589A (en) Therapeutic agents
RU2005141060A (ru) Метаболит кветиапина
WO2003041646A3 (en) L-dopa ethyl ester salts and uses thereof
WO2004077938A3 (en) Novel chemical entities and methods for their use in treatment of metabolic disorders
US20040266864A1 (en) Methods for treating depression and other CNS disorders using enantiomerically enriched desmethyl-and didesmethyl-metabolites of citalopram
IL142803A0 (en) Pharmaceutical compositions containing r-tofisopam
JP2004529936A5 (xx)
WO2004071152A3 (en) Use of s-10 hydroxy-10, 11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders
KR100882925B1 (ko) 세로토닌 5-ｈｔ₃ａ 길항적 효과를 갖는 피라졸 유도체함유 약제 조성물
KR101938738B1 (ko) 필로퀴논 또는 이의 유도체를 유효성분으로 포함하는 신경질환의 예방 또는 치료용 조성물
Gong et al. Role of brain monoamines in the fatal hyperthermia induced by pethidine or imipramine in rabbits pretreated with a monoamine oxidase inhibitor
NZ515613A (en) Chromeno[4,3,2-de]isoquinolines as potent dopamine receptor ligands
WO2008037416A3 (de) Verwendung von theogallin zur behandlung von mentalen konzentrationsleistungsstörungen, drepression und demenz
MX2008012212A (es) Metodos para tratar trastornos cognitivos y otros afines.
RU2010107460A (ru) (2s, 3r)-n-(2-((3-пиридинил)метил)-1-азабицикло[2.2.2]окт-3-ил)бензофуран-2-карбоксамид, новые солевые формы и способы их применения